Detalles de la búsqueda
1.
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
Br J Cancer;
127(3): 569-576, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35440668
2.
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets.
JTO Clin Res Rep;
5(2): 100623, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38357092
3.
Sepiapterin ameliorates chemically induced murine colitis and azoxymethane-induced colon cancer.
J Pharmacol Exp Ther;
347(1): 117-25, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23912334
4.
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
Clin Cancer Res;
29(16): 3237-3249, 2023 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37289191
5.
SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer.
Transl Lung Cancer Res;
10(11): 4095-4105, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35004241
6.
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
Cancer Res;
81(5): 1398-1412, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33402388
7.
Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer.
Cancer Metab;
9(1): 33, 2021 Sep 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34556188
8.
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.
Mol Cancer Res;
19(3): 485-497, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33172976
9.
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Cancer Cell;
39(3): 346-360.e7, 2021 03 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33482121
10.
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology.
J Thorac Oncol;
16(11): 1821-1839, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34274504
11.
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.
bioRxiv;
2021 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32577652
12.
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
J Thorac Oncol;
15(5): 777-791, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32068166
13.
Integrated Approaches for the Use of Large Datasets to Identify Rational Therapies for the Treatment of Lung Cancers.
Cancers (Basel);
11(2)2019 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30791396
14.
Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers.
Clin Cancer Res;
25(1): 346-357, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30257981
15.
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.
J Thorac Oncol;
14(12): 2152-2163, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31470128
16.
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
J Clin Oncol;
36(23): 2386-2394, 2018 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29906251
17.
In vivo analysis of a gain-of-function mutation in the Drosophila eag-encoded K+ channel.
Genetics;
172(4): 2351-8, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16452147
18.
A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients.
Oncotarget;
8(46): 81441-81454, 2017 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29113403
19.
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Oncotarget;
8(17): 28575-28587, 2017 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28212573
20.
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.
Oncotarget;
8(43): 73419-73432, 2017 Sep 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-29088717